2020 Q1 Form 10-Q Financial Statement
#000156459020022888 Filed on May 07, 2020
Income Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| Revenue | $51.22M | $99.07M |
| YoY Change | -48.3% | 48.94% |
| Cost Of Revenue | $9.080M | $7.990M |
| YoY Change | 13.64% | 25.18% |
| Gross Profit | $42.14M | $91.08M |
| YoY Change | -53.73% | 51.46% |
| Gross Profit Margin | 82.28% | 91.94% |
| Selling, General & Admin | $30.94M | $45.51M |
| YoY Change | -32.02% | 24.34% |
| % of Gross Profit | 73.41% | 49.97% |
| Research & Development | $25.46M | $35.73M |
| YoY Change | -28.75% | -23.87% |
| % of Gross Profit | 60.41% | 39.23% |
| Depreciation & Amortization | $200.0K | $200.0K |
| YoY Change | 0.0% | -85.07% |
| % of Gross Profit | 0.47% | 0.22% |
| Operating Expenses | $65.47M | $89.22M |
| YoY Change | -26.62% | 143.75% |
| Operating Profit | -$23.33M | $9.848M |
| YoY Change | -336.88% | -58.15% |
| Interest Expense | $3.068M | $4.443M |
| YoY Change | -30.95% | 311.77% |
| % of Operating Profit | 45.12% | |
| Other Income/Expense, Net | -$2.682M | -$19.94M |
| YoY Change | -86.55% | 1996.21% |
| Pretax Income | -$16.93M | -$10.09M |
| YoY Change | 67.82% | -58.56% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$16.93M | -$10.09M |
| YoY Change | 67.87% | -58.57% |
| Net Earnings / Revenue | -33.06% | -10.18% |
| Basic Earnings Per Share | -$0.43 | |
| Diluted Earnings Per Share | -$0.43 | -$262.2K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 39.29M | 38.50M |
| Diluted Shares Outstanding | 39.29M |
Balance Sheet
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $100.6M | $150.4M |
| YoY Change | -33.11% | 91.35% |
| Cash & Equivalents | $83.40M | $53.11M |
| Short-Term Investments | $17.20M | $101.6M |
| Other Short-Term Assets | $23.30M | $10.16M |
| YoY Change | 129.44% | -25.33% |
| Inventory | $3.300M | $2.600M |
| Prepaid Expenses | $11.98M | |
| Receivables | $27.00M | $81.00M |
| Other Receivables | $4.500M | $9.900M |
| Total Short-Term Assets | $158.7M | $256.2M |
| YoY Change | -38.05% | 130.36% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $3.085M | $3.718M |
| YoY Change | -17.03% | -13.53% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $6.300M | $6.900M |
| YoY Change | -8.7% | 1.47% |
| Total Long-Term Assets | $66.80M | $75.20M |
| YoY Change | -11.17% | 28.68% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $158.7M | $256.2M |
| Total Long-Term Assets | $66.80M | $75.20M |
| Total Assets | $225.5M | $331.4M |
| YoY Change | -31.95% | 95.33% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $17.30M | $28.88M |
| YoY Change | -40.09% | 22.57% |
| Accrued Expenses | $69.46M | $70.28M |
| YoY Change | -1.16% | 103.37% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $90.47M | $101.4M |
| YoY Change | -10.78% | 74.47% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $95.80M | $152.8M |
| YoY Change | -37.3% | 214.4% |
| Other Long-Term Liabilities | $29.90M | $33.60M |
| YoY Change | -11.01% | 510.91% |
| Total Long-Term Liabilities | $125.7M | $186.4M |
| YoY Change | -32.56% | 244.55% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $90.47M | $101.4M |
| Total Long-Term Liabilities | $125.7M | $186.4M |
| Total Liabilities | $216.2M | $287.9M |
| YoY Change | -24.92% | 156.6% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$1.295B | |
| YoY Change | ||
| Common Stock | $1.304B | |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $9.377M | $43.47M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $225.5M | $331.4M |
| YoY Change | -31.95% | 95.4% |
Cashflow Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$16.93M | -$10.09M |
| YoY Change | 67.87% | -58.57% |
| Depreciation, Depletion And Amortization | $200.0K | $200.0K |
| YoY Change | 0.0% | -85.07% |
| Cash From Operating Activities | -$11.54M | -$16.13M |
| YoY Change | -28.46% | 157.96% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $0.00 | |
| YoY Change | -100.0% | |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $34.38M | -$44.58M |
| YoY Change | -177.12% | |
| Cash From Investing Activities | $34.38M | -$44.58M |
| YoY Change | -177.11% | 111350.0% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 0.000 | 1.082M |
| YoY Change | -100.0% | -65.62% |
| NET CHANGE | ||
| Cash From Operating Activities | -11.54M | -16.13M |
| Cash From Investing Activities | 34.38M | -44.58M |
| Cash From Financing Activities | 0.000 | 1.082M |
| Net Change In Cash | 22.84M | -59.63M |
| YoY Change | -138.3% | 1795.45% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$11.54M | -$16.13M |
| Capital Expenditures | $0.00 | |
| Free Cash Flow | -$16.13M | |
| YoY Change | 156.32% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2020Q1 | us-gaap |
Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
|
true | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
|
true | |
| CY2020Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2019Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P6Y | |
| CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P5Y2M12D | |
| CY2020Q1 | pbyi |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
|
P9Y10M24D | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P5Y7M6D | |
| CY2020Q1 | pbyi |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
|
P9Y7M6D | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P4Y8M12D | |
| CY2020Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2735000 | |
| CY2020Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
90467000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
21930000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
22643000 | |
| CY2020Q1 | pbyi |
Post Marketing Commitment Liability Noncurrent
PostMarketingCommitmentLiabilityNoncurrent
|
8000000 | |
| CY2019Q4 | pbyi |
Post Marketing Commitment Liability Noncurrent
PostMarketingCommitmentLiabilityNoncurrent
|
9000000 | |
| CY2020Q1 | us-gaap |
Long Term Debt
LongTermDebt
|
95755000 | |
| CY2019Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
94962000 | |
| CY2020Q1 | us-gaap |
Liabilities
Liabilities
|
216152000 | |
| CY2019Q4 | us-gaap |
Liabilities
Liabilities
|
217442000 | |
| CY2020Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2019Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2020Q1 | pbyi |
Post Marketing Commitment Liability Current
PostMarketingCommitmentLiabilityCurrent
|
1000000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
12000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
60211000 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
39317221 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
39317221 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
39203304 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
39203304 | |
| CY2020Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
4000 | |
| CY2019Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
4000 | |
| CY2020Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
1303940000 | |
| CY2019Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
1295033000 | |
| CY2020Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
2000 | |
| CY2019Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
62000 | |
| CY2020Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1294569000 | |
| CY2019Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1277636000 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
9377000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
17463000 | |
| CY2020Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
225529000 | |
| CY2019Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
234905000 | |
| CY2020Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
25455000 | |
| CY2019Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
35728000 | |
| CY2020Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
65468000 | |
| CY2019Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
89219000 | |
| CY2019Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
9848000 | |
| CY2020Q1 | us-gaap |
Interest Expense
InterestExpense
|
3068000 | |
| CY2020Q1 | pbyi |
Legal Verdict Expenses
LegalVerdictExpenses
|
93000 | |
| CY2019Q1 | pbyi |
Legal Verdict Expenses
LegalVerdictExpenses
|
16350000 | |
| CY2020Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
93000 | |
| CY2019Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-14000 | |
| CY2020Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-2682000 | |
| CY2019Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-19935000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16933000 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10087000 | |
| CY2020Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-16933000 | |
| CY2019Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-10087000 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.43 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.26 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
39291162 | |
| CY2019Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
38481824 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
|
0 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
|
0 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-63000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
32000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
|
0 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
|
0 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
|
-3000 | |
| CY2020Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-16993000 | |
| CY2019Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-10055000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
17463000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
|
-3000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-63000 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
9377000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
34306000 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
18138000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
1082000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
32000 | |
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
43471000 | |
| CY2020Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-16933000 | |
| CY2019Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-10087000 | |
| CY2020Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1916000 | |
| CY2019Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
2135000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
8907000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
18138000 | |
| CY2019Q1 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-1000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
2646000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
127000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
1140000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
-1230000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
-18000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
8368000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1928000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
8194000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
434000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
23850000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
|
41000 | |
| CY2019Q1 | pbyi |
Increase Decrease In Post Marketing Commitment Liability
IncreaseDecreaseInPostMarketingCommitmentLiability
|
9000000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-11540000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-16130000 | |
| CY2020Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
34377000 | |
| CY2019Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
42132000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
34377000 | |
| CY2019Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
1082000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
1082000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
22837000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-59631000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
73210000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
112738000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
96047000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
53107000 | |
| CY2020Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
2275000 | |
| CY2019Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
3228000 | |
| CY2020Q1 | pbyi |
Number Of Subsidiaries
NumberOfSubsidiaries
|
2 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16900000 | |
| CY2020Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
83400000 | |
| CY2020Q1 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
17200000 | |
| CY2020Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2020Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates: </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the balance sheet, and reported amounts of revenues and expenses for the period presented. Accordingly, actual results could differ from those estimates. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant estimates include estimates for variable consideration for which reserves were established. These estimates are included in the calculation of net revenues and include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the Company’s sale of its products. </p> | |
| CY2020Q1 | pbyi |
Incremental Costs Expenses
IncrementalCostsExpenses
|
0 | |
| CY2020Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
12700000 | |
| CY2019Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
13200000 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
93222000 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
4000 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
2000 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
93224000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
92840000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
62000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
92902000 | |
| CY2020Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Risk: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents, marketable securities, and accounts receivable, net. The Company’s cash and cash equivalents and restricted cash in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at March 31, 2020, were approximately $98.6 million. The Company does not believe it is exposed to any significant credit risk due to the quality nature of the financial instruments in which the money is held. Pursuant to the Company’s internal investment policy, investments must be rated A-1/P-1 or better by Standard and Poor’s Rating Service and Moody’s Investors Service at the time of purchase. </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sells its products in the United States primarily through specialty pharmacies and specialty distributors. Therefore, wholesale distributors and large pharmacy chains account for a large portion of its accounts receivables, net and product revenues, net. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for doubtful accounts primarily based on the credit worthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions. The Company recorded $0 as an allowance for doubtful accounts in the three months ended March 31, 2020 and 2019.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s success depends on its ability to successfully commercialize NERLYNX. The Company currently has a single product with limited commercial sales experience, which makes it difficult to evaluate its current business, predict its future prospects and forecast financial performance and growth. The Company has invested a significant portion of its efforts and financial resources in the development and commercialization of the lead product, NERLYNX, and expects NERLYNX to constitute the vast majority of product revenue for the foreseeable future. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company relies exclusively on third parties to formulate and manufacture NERLYNX and its drug candidates. The commercialization of NERLYNX and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those third parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company has no experience in drug formulation or manufacturing and does not intend to establish its own manufacturing facilities. The Company lacks the resources and expertise to formulate or manufacture NERLYNX and other drug candidates. While the drug candidates were being developed by Pfizer, both the drug substance and drug product were manufactured by third-party contractors. The Company is using the same third-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and the commercialization of NERLYNX. If the Company is unable to continue its relationships with one or more of these third-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on one or more third-party contractors to manufacture the commercial supply of drugs.</span></p> | |
| CY2020Q1 | pbyi |
Cash And Cash Equivalents And Restricted Cash In Excess Of Insured Limits
CashAndCashEquivalentsAndRestrictedCashInExcessOfInsuredLimits
|
98600000 | |
| CY2020Q1 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
0 | |
| CY2019Q1 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
0 | |
| CY2017 | pbyi |
Research And Development Expense Related To Inventory
ResearchAndDevelopmentExpenseRelatedToInventory
|
4500000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
|
Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Option To Terminate
LesseeOperatingLeaseOptionToTerminate
|
Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise | |
| CY2020Q1 | pbyi |
Average Incremental Borrowing Rate
AverageIncrementalBorrowingRate
|
0.109 | |
| CY2019 | pbyi |
Reduction In Carrying Value Of Right Of Use Assets
ReductionInCarryingValueOfRightOfUseAssets
|
1200000 | |
| CY2020Q1 | pbyi |
Accounts Receivable Net Excluding License Revenue Receivable
AccountsReceivableNetExcludingLicenseRevenueReceivable
|
27042000 | |
| CY2019Q4 | pbyi |
Accounts Receivable Net Excluding License Revenue Receivable
AccountsReceivableNetExcludingLicenseRevenueReceivable
|
26396000 | |
| CY2020Q1 | pbyi |
License Revenue Receivable
LicenseRevenueReceivable
|
4500000 | |
| CY2019Q4 | pbyi |
License Revenue Receivable
LicenseRevenueReceivable
|
2500000 | |
| CY2020Q1 | us-gaap |
Accounts Receivable Net
AccountsReceivableNet
|
31542000 | |
| CY2019Q4 | us-gaap |
Accounts Receivable Net
AccountsReceivableNet
|
28896000 | |
| CY2020Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
13937000 | |
| CY2019Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
13259000 | |
| CY2020Q1 | us-gaap |
Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
|
2461000 | |
| CY2019Q4 | us-gaap |
Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
|
1999000 | |
| CY2020Q1 | us-gaap |
Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
|
16398000 | |
| CY2019Q4 | us-gaap |
Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
|
15258000 | |
| CY2020Q1 | pbyi |
Fixed Lease Expense
FixedLeaseExpense
|
1200000 | |
| CY2020Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
100000 | |
| CY2019Q1 | pbyi |
Fixed Lease Expense
FixedLeaseExpense
|
1200000 | |
| CY2019Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
100000 | |
| CY2020Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1400000 | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.109 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
3933000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
5365000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
5483000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
5631000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
5805000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
7490000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
33707000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
9042000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
24665000 | |
| CY2020Q1 | us-gaap |
Sublease Income
SubleaseIncome
|
100000 | |
| CY2020Q1 | us-gaap |
Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
|
341000 | |
| CY2020Q1 | us-gaap |
Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
|
467000 | |
| CY2020Q1 | us-gaap |
Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
|
481000 | |
| CY2020Q1 | us-gaap |
Lessor Operating Lease Payments To Be Received Four Years
LessorOperatingLeasePaymentsToBeReceivedFourYears
|
495000 | |
| CY2020Q1 | us-gaap |
Lessor Operating Lease Payments To Be Received Five Years
LessorOperatingLeasePaymentsToBeReceivedFiveYears
|
510000 | |
| CY2020Q1 | us-gaap |
Lessor Operating Lease Payments To Be Received Thereafter
LessorOperatingLeasePaymentsToBeReceivedThereafter
|
659000 | |
| CY2020Q1 | us-gaap |
Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
|
2953000 | |
| CY2020Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
9177000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
9163000 | |
| CY2020Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
6092000 | |
| CY2019Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
5859000 | |
| CY2020Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
3085000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
3304000 | |
| CY2020Q1 | us-gaap |
Depreciation
Depreciation
|
200000 | |
| CY2019Q1 | us-gaap |
Depreciation
Depreciation
|
200000 | |
| CY2020Q1 | us-gaap |
Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
|
50000000 | |
| CY2020Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
10526000 | |
| CY2020Q1 | us-gaap |
Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
|
39474000 | |
| CY2020Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1000000.0 | |
| CY2019Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1000000.0 | |
| CY2020Q1 | pbyi |
Accrued Legal Verdict Expense Current
AccruedLegalVerdictExpenseCurrent
|
31443000 | |
| CY2019Q4 | pbyi |
Accrued Legal Verdict Expense Current
AccruedLegalVerdictExpenseCurrent
|
31350000 | |
| CY2020Q1 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
7783000 | |
| CY2019Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
8866000 | |
| CY2020Q1 | pbyi |
Accrued Development Costs
AccruedDevelopmentCosts
|
6811000 | |
| CY2019Q4 | pbyi |
Accrued Development Costs
AccruedDevelopmentCosts
|
8502000 | |
| CY2020Q1 | pbyi |
Accrued Variable Consideration Current
AccruedVariableConsiderationCurrent
|
9709000 | |
| CY2019Q4 | pbyi |
Accrued Variable Consideration Current
AccruedVariableConsiderationCurrent
|
7978000 | |
| CY2020Q1 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
2271000 | |
| CY2019Q4 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
1618000 | |
| CY2020Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
4196000 | |
| CY2019Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
4138000 | |
| CY2020Q1 | pbyi |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
2044000 | |
| CY2019Q4 | pbyi |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
2546000 | |
| CY2020Q1 | pbyi |
Accrued Professional Fees Liability Current
AccruedProfessionalFeesLiabilityCurrent
|
1940000 | |
| CY2019Q4 | pbyi |
Accrued Professional Fees Liability Current
AccruedProfessionalFeesLiabilityCurrent
|
1775000 | |
| CY2020Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
646000 | |
| CY2019Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
266000 | |
| CY2020Q1 | pbyi |
Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
|
1327000 | |
| CY2019Q4 | pbyi |
Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
|
869000 | |
| CY2020Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1294000 | |
| CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1122000 | |
| CY2020Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
69464000 | |
| CY2019Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
69030000 | |
| CY2020Q1 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
100000000 | |
| CY2020Q1 | us-gaap |
Debt Instrument Maturity Date
DebtInstrumentMaturityDate
|
2024-06-01 | |
| CY2020Q1 | pbyi |
Accretion Of Final Interest Payment
AccretionOfFinalInterestPayment
|
2260000 | |
| CY2020Q1 | us-gaap |
Deferred Finance Costs Net
DeferredFinanceCostsNet
|
6505000 | |
| CY2020Q1 | us-gaap |
Long Term Debt
LongTermDebt
|
95755000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
|
113417 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
|
192912 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2020Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2020Q1 | us-gaap |
Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
|
2021-10-04 | |
| CY2020Q1 | pbyi |
Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
|
8907000 | |
| CY2019Q1 | pbyi |
Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
|
18138000 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5042325 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
82.42 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
1951000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
606800 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
9.96 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
500 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
3.75 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
5000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
286638 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
84.66 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5361987 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
74.10 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
1974000 | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
975127 | |
| CY2020Q1 | pbyi |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice
|
14.66 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
4386860 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
87.32 | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
1635000 | |
| CY2019Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
439194 | |
| CY2019Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
|
19.38 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
606800 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
7.86 | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
|
70867 | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
|
29.61 | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
975127 | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
|
11.47 | |
| CY2019Q1 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
400000 | |
| CY2020Q1 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
400000 | |
| CY2020Q1 | pbyi |
Milestone Payments Maximum Amount
MilestonePaymentsMaximumAmount
|
187500000 | |
| CY2020Q1 | pbyi |
Success Based Legal Fee
SuccessBasedLegalFee
|
3000000.0 |
